Endo Tools Therapeutics SA: Enabling Natural Orifice GI Procedures

Belgium-based Endo Tools Therapeutics SA is developing devices that will enable NOTES procedures to treat disorders such as type 2 diabetes, morbid obesity, and digestive tract tumors. Its Endomina device is a universal, multi-channel triangulation platform for use on any existing endoscope through the natural orifices, such as the esophagus.

Belgium-based Endo Tools Therapeutics SA aims to enable natural orifice translumenal endoscopic surgery (NOTES) for treating disorders such as type 2 diabetes, morbid obesity, and digestive tract tumors. Its Endomina is a universal triangulation platform for use with any existing endoscope through the natural orifices, such as the mouth and esophagus. The single-use, flexible device consists of two therapeutic hollow channels that attach to a standard endoscope after insertion in the patient’s stomach. It allows for multiple small tools such as a small-tissue grasper, an electric tissue cutter, or a needle for a suture to be introduced and removed during a procedure, with up to three tools used at the same time. At the end of the channels, Endomina also features two arms that are silicon-enclosed and controlled via joysticks to ensure independent control and position reset. The tip of the device replicates the movements from the joysticks to perform remote surgical actions. In addition, movements are transmitted using mechanical wires in Endomina to avoid any electricity flow in the patient. (See Also see "Obesity Intervention: A New Era Of Discovery And Innovation" - Medtech Insight, 7 December, 2012., Also see "Trends In MIS, Part I: Pushing Surgical Boundaries" - Medtech Insight, 25 May, 2012., Also see "Trends In MIS: Part II" - Medtech Insight, 6 July, 2012., and Also see "The Future of Laparoscopy: Single Incision, NOTES and Robots " - Medtech Insight, 1 July, 2010..)

“We can make very complex movements – suturing, lifting tissues – in the patient, without resorting to laparoscopy or open...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Aneira Health Launches New Precision Medicine Platform Exclusively For Women

 

Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit

 
• By 

Thermo Fisher is aggressively managing its supply chain and cost base using its Practical Process Improvement (PPI) Business System. The company is also increasing investments in US-based manufacturing and R&D, with around $2bn allocated to bolster domestic operations.